Eli Lilly's dominance in the GLP-1 market and strong revenue growth forecast make LLY stock a promising investment, with a ...
County Public Schools has joined dozens of other school systems and institutions in suing pharmaceutical and pharmacy companies, alleging that the companies manipulated the prices of insulin and other ...
Johnson & Johnson stock (NYSE: JNJ) lost about 7% in 2024, underperforming the broader S&P 500 index, which gained 23% for ...
Scorpion’s drug candidate inhibits a mutation that is a major driver of breast, gynaecological and head and neck cancers ...
Kristin Sherman leads startup Kovina Therapeutics, which is still in the early stages of developing ways to stop human ...
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
Eli Lilly (NYSE:LLY) has entered into a licensing agreement with Mediar Therapeutics to advance Mediar's drug MTX-463 into ...
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 494.50% and ...
Eli Lilly (LLY) is in advanced talks to buy cancer-focused biotech Scorpion Therapeutics in a deal worth up to $2.5B, people close to the talks ...
Hosted on MSN23h
Do TNF Inhibitors Really Worsen RA-Associated Lung Disease?Worries that tumor necrosis factor (TNF) inhibitors may exacerbate or even cause lung disease in patients with rheumatoid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback